Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study

Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted. To compare the real-world effectiveness of TFM versus DMF. Anonymized data were collected from patients with relapsing multiple sclerosis (MS) initiating treatment with teriflunomide (N = 50)...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2019-04, Vol.8 (5), p.305-316
Main Authors: Zivadinov, Robert, Kresa-Reahl, Kiren, Weinstock-Guttman, Bianca, Edwards, Keith, Burudpakdee, Chakkarin, Bergsland, Niels, Dwyer, Michael G, Khatri, Bhupendra, Thangavelu, Karthinathan, Chavin, Jeffrey, Mandel, Matt, Cohan, Stanley
Format: Article
Language:English
Subjects:
Arthritis
Atrophy
brain volume
Clinical medicine
Clinical trials
dimethyl fumarate
Medical imaging
MRI
Multiple sclerosis
NMR
Nuclear magnetic resonance
Oral diseases
Patients
Performance evaluation
relapsing forms of MS
retrospective study
Software
Studies
teriflunomide
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted. To compare the real-world effectiveness of TFM versus DMF. Anonymized data were collected from patients with relapsing multiple sclerosis (MS) initiating treatment with teriflunomide (N = 50) or DMF (N = 50). On follow-up magnetic resonance imaging (MRI) compared with baseline, with TFM versus DMF treatment, the proportion of patients with new/enlarging T2 or gadolinium-enhancing lesions was 30.0 versus 40.0% (p = 0.2752). However, median annualized percent whole brain volume change was -0.1 versus -0.5 (p = 0.0212). There were no significant treatment differences on additional MRI and clinical end points and no unexpected safety signals. The effectiveness of teriflunomide was superior to DMF on whole brain atrophy and similar to DMF on other MRI/clinical end points.
ISSN:2042-6305
2042-6313
DOI:10.2217/cer-2018-0135